异丙基二异丙氧基硼烷 | 103885-29-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 异丙基二异丙氧基硼烷
• 英文名称: isopropyldiisopropoxyborane
• 英文别名: triisopropyl boronate；boronic acid triisopropyl ester；propan-2-yl-di(propan-2-yloxy)borane
• CAS: 103885-29-6
• 化学式: C₉H₂₁BO₂
• 分子量: 172.076
• InChiKey: UKCYZZJQSYCZQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  138 °C(Press: 749 Torr)
• 密度：
  0.808±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.73
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基丁烷-1,3-二醇 、 异丙基二异丙氧基硼烷 生成 4,5-dimethyl-2-isopropyl-1,3,2-dioxaborinane
  参考文献：
  名称：

  KUZNETSOV, V. V.;GREN, A. I., ZH. OBSHCH. XIMII, 1986, 56, N 3, 613-616

  摘要：

  DOI：
• 作为产物：
  描述：

  硼酸三异丙酯 生成 异丙基二异丙氧基硼烷
  参考文献：
  名称：

  BROWN, HERBERT C.

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-(2-溴苯基)哌嗪-1-羧酸叔丁酯 在 正丁基锂 、 异丙基二异丙氧基硼烷 、 水 、 氯化铵 作用下， 以 四氢呋喃 、 正己烷 、 异丙醇 为溶剂， 反应 2.67h， 生成 2-[4-(N-叔丁)哌嗪]苯嘧啶-5-硼酸酯
  参考文献：
  名称：

  WO2006/126635

  摘要：

  公开号：

文献信息

• [EN] 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS<br/>[FR] 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES UTILISEES COMME ANTAGONISTES DU RECEPTEUR DE L'HORMONE CONCENTRANT LA MELANINE, ET COMPOSITIONS ET PROCEDES ASSOCIES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005103039A1

  公开（公告）日：2005-11-03

  Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, Het, X and Cyc are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

  黑色素浓缩激素（MCH）受体拮抗剂被披露具有治疗基于MCH受体的疾病如肥胖的效用。本发明的化合物具有以下结构：包括立体异构体、前药和其药用盐，其中R1、R2、R5、Het、X和Cyc如本文所定义。还披露了含有本发明化合物的组合物，以及与其使用相关的方法。
• Process for lithium mono- and diorganylborohydrides
  申请人：Aldrich-Boranes, Inc.

  公开号：US04772751A1

  公开（公告）日：1988-09-20

  Improved processes for liberating boronic, RB(OR').sub.2, and borinic, RR'BOR', esters from their "ate" complexes, free of alcohol are provided. Pyrolysis of lithium organylborates LiRB(OR').sub.3 and LiRR'BOR', wherein R is an organyl group and R' is straight or branched-chain lower alkyl, directly yields the relatively volatile boronic and borinic esters in high purity, leaving behind a residue of lithium alkoxide. Treatment of the lithium organylborates with an appropriate acid halide cleanly liberates either volatile or non-volatile boronic or borinic esters, readily separated from the lower alkyl ester produced as a by-product. The novel compound lithium dimethylborohydride is also provided.

  提供了一种改进的过程，用于从其“醇盐”络合物中解离出硼酸酯，RB（OR'）2和硼烷酸酯，RR'BOR'，不含醇。锂有机硼酸盐LiRB（OR'）3和LiRR'BOR'的热解，其中R是有机基团，R'是直链或支链低级烷基，直接产生相对挥发性的高纯度硼酸酯和硼烷酸酯，留下锂醇盐残留物。用适当的酸卤处理锂有机硼酸盐可以干净地解离出挥发性或非挥发性的硼酸酯或硼烷酸酯，很容易与产生的低级酯副产物分离。还提供了新型化合物锂二甲基硼氢化物。
• Improved process for producing pure boronic and borinic esters
  申请人：Aldrich-Boranes, Inc.

  公开号：US04870177A1

  公开（公告）日：1989-09-26

  Improved processes for liberating boronic, RB(OR').sub.2, and borinic, RR'BOR', esters from their "ate" complexes, free of alcohol are provided. Pyrolysis of lithium organylborates LiRB(OR').sub.3 and LiRR'BOR', wherein R is an organyl group and R' is straight or branched-chain lower alkyl, directly yields the relatively volatile boronic and borinic esters in high purity, leaving behind a residue of lithium alkoxide. Treatment of the lithium organylborates with an appropriate acid halide cleanly liberates either volatile or non-volatile boronic or borinic esters, readily separated from the lower alkyl ester produced as a by-product. The novel compound lithium dimethylborohydride is also provided.

  提供了从它们的“ate”配合物中解放出无醇的硼酸酯，RB（OR'）2和硼烷酸酯，RR'BOR'的改进过程。热解锂有机硼酸盐LiRB（OR'）3和LiRR'BOR'，其中R是有机基团，R'是直链或支链低碳链烷基，直接产生相对挥发性的高纯度硼酸酯和硼烷酸酯，留下锂烷氧化物的残留物。用适当的酸卤处理锂有机硼酸盐可以干净地解放出挥发性或非挥发性的硼酸酯或硼烷酸酯，容易与产生的低碳链酯副产物分离。还提供了新型化合物锂二甲基硼氢化物。
• Dihydropyrazolopyrimidinone derivatives
  申请人：Sagara Takeshi

  公开号：US20070254892A1

  公开（公告）日：2007-11-01

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及通式（I）的化合物：其中Ar1是可选取代的芳基或杂环芳基基团；R1是可选取代的较低烷基、较低烯基、较低炔基或环-较低烷基基团，或是可选取代的芳基、芳基烷基或杂环芳基基团，可具有取代基；R2是氢原子、较低烷基基团、较低烯基基团或较低炔基基团，或是可选取代的芳基、芳基烷基或杂环芳基基团，可具有取代基；R3是氢原子或较低烷基基团；R4是氢原子、卤素原子、羟基、较低烷基或—N（R1k）R1m的基团；T和U是氮原子或甲基基团等。本发明的化合物具有优异的Weel激酶抑制作用，因此在药物领域，特别是治疗各种癌症方面有用。
• Dihydropyrazolopyrimidinone Derivatives
  申请人：Sakamoto Toshihiro

  公开号：US20100063024A1

  公开（公告）日：2010-03-11

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式（I）的化合物：其中Ar1是可选取取代基的芳基或杂环芳基基团；R1是可选取取代基的低碳基、低烯基、低炔基或环低碳基基团，或是带取代基的芳基、芳基烷基或杂环芳基基团；R2是氢原子、低碳基、低烯基或低炔基，或是带取代基的芳基、芳基烷基或杂环芳基基团；R3是氢原子或低碳基；R4是氢原子、卤素原子、羟基、低碳基或-N（R1k）R1m基团；T和U是氮原子或甲基烷基等。本发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。